Jacob Bor1,2,3,4, Calvin Chiu1, Shahira Ahmed1,2, Ingrid Katz5,6,7, Matthew P Fox1,2,4, Sydney Rosen1,2, Manisha Yapa3, Frank Tanser3,8,9, Deenan Pillay3,10, Till Bärnighausen3,9,11,12. 1. Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2. Department of Global Health, Boston University School of Public Health, Boston, MA, USA. 3. Africa Health Research Institute, KwaZulu-Natal, South Africa. 4. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. 5. Division of Women's Health, Brigham and Women's Hospital, Boston, MA, USA. 6. Center for Global Health, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 7. Harvard Medical School, Boston, MA, USA. 8. School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. 9. Research Department of Infection & Population Health, University College London, London, United Kingdom. 10. Department of Virology, University College London, London, United Kingdom. 11. Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America. 12. Institute of Public Health, University of Heidelberg, Heidelberg, Germany.
Abstract
OBJECTIVES: To assess the relationship between CD4 count at presentation and ART uptake and assess predictors of timely treatment initiation in rural KwaZulu-Natal, South Africa. METHODS: We used Kaplan-Meier and Cox proportional hazards models to assess the association between first CD4 count and time from first CD4 to ART initiation among all adults presenting to the Hlabisa HIV Treatment and Care Programme between August 2011 and December 2012 with treatment-eligible CD4 counts (≤ 350 cells/mm3 ). For a subset of healthier patients (200 < CD4 ≤ 350 cells) residing within the population surveillance of the Africa Health Research Institute, we assessed sociodemographic, economic and geographic predictors hypothesised to influence ART uptake. RESULTS: A total of 4739 patients presented for care with eligible CD4 counts. The proportion initiating ART within six months of diagnosis was 67% (95% CI 63, 71) in patients with CD4 ≤ 50, 59% (0.55, 0.63) in patients with CD4 151-200 and 48% (95% CI 44, 51) in patients with CD4 301-350. The hazard of starting ART fell by 17% (95% CI 14, 20) for every 100-cell increase in baseline CD4 count. Among healthier patients under demographic surveillance (n = 193), observable sociodemographic, economic and geographic predictors did not add discriminatory power beyond CD4 count, age and sex to identify patients at high risk of non-initiation. CONCLUSIONS: Individuals presenting for HIV care at higher CD4 counts were less likely to initiate ART than patients presenting at low CD4 counts. Overall, ART uptake was low. Under new guidelines that establish ART eligibility regardless of CD4 count, patients with high CD4 counts may require additional interventions to encourage treatment initiation.
OBJECTIVES: To assess the relationship between CD4 count at presentation and ART uptake and assess predictors of timely treatment initiation in rural KwaZulu-Natal, South Africa. METHODS: We used Kaplan-Meier and Cox proportional hazards models to assess the association between first CD4 count and time from first CD4 to ART initiation among all adults presenting to the Hlabisa HIV Treatment and Care Programme between August 2011 and December 2012 with treatment-eligible CD4 counts (≤ 350 cells/mm3 ). For a subset of healthier patients (200 < CD4 ≤ 350 cells) residing within the population surveillance of the Africa Health Research Institute, we assessed sociodemographic, economic and geographic predictors hypothesised to influence ART uptake. RESULTS: A total of 4739 patients presented for care with eligible CD4 counts. The proportion initiating ART within six months of diagnosis was 67% (95% CI 63, 71) in patients with CD4 ≤ 50, 59% (0.55, 0.63) in patients with CD4 151-200 and 48% (95% CI 44, 51) in patients with CD4 301-350. The hazard of starting ART fell by 17% (95% CI 14, 20) for every 100-cell increase in baseline CD4 count. Among healthier patients under demographic surveillance (n = 193), observable sociodemographic, economic and geographic predictors did not add discriminatory power beyond CD4 count, age and sex to identify patients at high risk of non-initiation. CONCLUSIONS: Individuals presenting for HIV care at higher CD4 counts were less likely to initiate ART than patients presenting at low CD4 counts. Overall, ART uptake was low. Under new guidelines that establish ART eligibility regardless of CD4 count, patients with high CD4 counts may require additional interventions to encourage treatment initiation.
Keywords:
zzm321990ARTzzm321990; zzm321990HIVzzm321990; ART; Afrique du Sud; South Africa; VIH; cascade de soins; cascade of care; demographic surveillance; failure to initiate; surveillance démographique; échec à initier
Authors: Nuala McGrath; Judith R Glynn; Jacqueline Saul; Katharina Kranzer; Andreas Jahn; Frank Mwaungulu; Msenga H C Ngwira; Hazzie Mvula; Fipson Munthali; Venance Mwinuka; Lorren Mwaungulu; Paul E M Fine; Amelia C Crampin Journal: BMC Public Health Date: 2010-10-12 Impact factor: 3.295
Authors: Ingrid T Katz; Janan Dietrich; Gugu Tshabalala; Thandekile Essien; Kathryn Rough; Alexi A Wright; David R Bangsberg; Glenda E Gray; Norma C Ware Journal: AIDS Behav Date: 2015-04
Authors: Toyin Togun; Ingrid Peterson; Shabbar Jaffar; Francis Oko; Uduak Okomo; Kevin Peterson; Assan Jaye Journal: AIDS Res Ther Date: 2011-07-20 Impact factor: 2.250
Authors: Jacob Bor; Matthew P Fox; Sydney Rosen; Atheendar Venkataramani; Frank Tanser; Deenan Pillay; Till Bärnighausen Journal: PLoS Med Date: 2017-11-28 Impact factor: 11.613
Authors: Maria F Nardell; Bethany Hedt-Gauthier; Valerie A Earnshaw; Laura M Bogart; Janan J Dietrich; Ingrid Courtney; Gugulethu Tshabalala; Jacob Bor; Catherine Orrell; Glenda Gray; David R Bangsberg; Ingrid T Katz Journal: AIDS Behav Date: 2021-10-27
Authors: William B MacLeod; Jacob Bor; Sue Candy; Mhairi Maskew; Matthew P Fox; Katia Bulekova; Alana T Brennan; James Potter; Cornelius Nattey; Dorina Onoya; Koleka Mlisana; Wendy Stevens; Sergio Carmona Journal: BMJ Open Date: 2022-10-19 Impact factor: 3.006
Authors: Shahira Ahmed; Jessica Autrey; Ingrid T Katz; Matthew P Fox; Sydney Rosen; Dorina Onoya; Till Bärnighausen; Kenneth H Mayer; Jacob Bor Journal: Soc Sci Med Date: 2018-05-30 Impact factor: 4.634
Authors: Karla Therese L Sy; Shema Tariq; Gita Ramjee; Kelly Blanchard; Cheng-Shiun Leu; Elizabeth A Kelvin; Theresa M Exner; Anisha D Gandhi; Naomi Lince-Deroche; Joanne E Mantell; Lucia F O'Sullivan; Susie Hoffman Journal: PLoS One Date: 2021-02-19 Impact factor: 3.240
Authors: Catherine Orrell; Kathy Goggin; Ingrid T Katz; Laura M Bogart; Garrett M Fitzmaurice; Vincent S Staggs; Marya V Gwadz; Ingrid V Bassett; Anna Cross; Ingrid Courtney; Lungiswa Tsolekile; Regina Panda; Sonja Steck; David R Bangsberg Journal: AIDS Behav Date: 2020-10-30
Authors: Ingrid T Katz; Nicholas Musinguzi; Kathleen Bell; Anna Cross; Mwebesa B Bwana; Gideon Amanyire; Stephen Asiimwe; Catherine Orrell; David R Bangsberg; Jessica E Haberer Journal: J Acquir Immune Defic Syndr Date: 2021-04-15 Impact factor: 3.771